ICICI Securities
-
Cholamandalam Sees Rating Upgrade From ICICI Securities — Check Target Price
The brokerage believe its recent under performance stems largely from concerns about near-term asset quality amid rising oil prices. However, its analysis suggests Chola has emerged as the most resilient VF player during past cycles.
-
Generic GLP-1 Race Set To Begin In India; Pharma Stocks In Focus — Read ICICI Securities Report
ICICI Securities noted that Torrent Pharma is currently the only listed Indian pharma company to have disclosed the launch of a generic oral semaglutide, positioning it as an early mover in this segment.
-
LG Electronics: ICICI Securities Hikes Target Price Citing Multiple Growth Triggers — Do You Own The Stock?
LG remains well placed to benefit from favorable summer conditions, premiumisation trends, and ongoing capacity expansion in room air conditioners, adds ICICI Securities.
-
Coforge, Mphasis, LTIMindtree Get Rating Upgrades From ICICI Securities — Check Bull, Base, And Bear Cases
The brokerage retains Buy on Hexaware and LatentView.
-
KFin Technologies: ICICI Securities Upgrades Stock To 'Buy' But Trims Target Price — Here's Why
ICICI Securities said the investment thesis on KFIN Technologies remains intact, underpinned by multiple long-term growth drivers.
-
CDSL Shares In Focus After ICICI Securities Cuts Target Price — Here's Why
Available positive and negative levers underpins brokerage's Hold rating on CDSL - Details inside
-
HDB Financial Gets ICICI Securities' Buy Initiation — Check Target Price, Potential Upside And More
ICICI Securities remain confident in HDB's ability to deliver long-term shareholder value backed by multiple growth triggers.
-
Hexaware Bags Motilal Oswal's 'Buy' Initiation Citing Attractive Valuations — Check Target Price
While ICICI Securities maintains that IT services face no existential threat, valuation multiples are likely to remain suppressed in the near term.
-
Why ONGC, Oil India Remain ICICI Securities' Tactical 'Buy' While Peers Struggle — Details Inside
ICICI Securities has kept its ratings unchanged across the oil and gas basket for now, but highlights that tactical strength lies firmly with ONGC and Oil India in the near term.
-
Healthcare Stocks To Buy: Fortis, Metropolis Lead ICICI Securities' Top Picks — Check Full List
ICICI Securities highlighted Fortis, Metropolis among others as its top picks within the sector, citing strong operating momentum, execution visibility, and favorable demand trends.
-
Pharma Stocks To Buy: Aurobindo, Sun Pharma Lead ICICI Securities' Top Picks — Check Full List
Pharma companies' revenue growth was mainly led by India, while US, on constant currency basis, grew mere 1.4% YoY.
-
Fortis Shares Upgraded To 'Buy' By ICICI Securities After Q3 Results — Check Revised Target Price
ICICI Securities expects a 26.1% Ebitda CAGR over FY2528E driven by a revenue CAGR of 19.2%.
-
LG Electronics Posts Muted Q3 Margins; Market Share Gains Sustain, Says ICICI Securities — Check Target Price
With strong brand equity, sustained leadership, distribution strength and backward integration, LG is well-positioned to deliver consistent growth.
-
Ashok Leyland Q3 Review: ICICI Securities Maintains 'Buy' Post Healthy Quarter — Check Hiked Target Price
Product premiumisation and focus on better servicing are driving market share gains for Ashok Leyland across MHCV and LCV segments
-
Aurobindo Pharma Shares In Focus After Q3 Results; This Brokerage Maintains A Bullish View — More Details Inside
The brokerage noted that Aurobindo is expected to complete the Rs 2,075 crore acquisition of Lannett in Q1 FY27, which may add nearly 7% to FY27 US revenue growth.
